IP Library Granted Patent US 8,268,326
Granted Patent B2
US 8,268,326 · App. 12/244,828 · Granted Sep 18, 2012

Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof

Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,326
App. No.
12/244,828
Granted
Sep 18, 2012
Kind
B2
Abstract

This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant Listeria strains comprising same, and methods of inducing an anti-HMW-MAA and anti HER-2/neu immune response thus treating and impeding the growth of tumors, comprising administering same.

Claims (7)

1. A method of delaying progression of a breast tumor in a subject, said method comprising the step of administering to said subject a composition comprising a recombinant Listeria strain expressing a recombinant nucleotide sequence encoding a recombinant polypeptide comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) protein fused to a listeriolysin (LLO) protein, an ActA protein, or a PEST sequence, wherein said recombinant nucleotide sequence encoding said fragment is selected from the group consisting of SEQ ID NOs 21, 22, or 23, whereby said subject mounts an immune response against a HMW-MAA-expressing pericyte of a vasculature of said tumor, whereby said subject mounts an immune response against said pericyte of said vasculature of said tumor, thereby delaying progression of a breast tumor in a subject.

2. A method of treating, suppressing, or inhibiting a breast cancer in a subject, whereby said breast cancer is associated with expression of HER-2/neu antigen in said subject, said method comprising the step of administering to said subject a composition comprising a recombinant Listeria strain expressing a recombinant nucleotide sequence encoding a recombinant polypeptide comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) protein fused to a listeriolysin (LLO) protein, an ActA protein, or a PEST sequence, wherein said recombinant nucleotide sequence encoding said fragment is selected from the group consisting of SEQ ID NOs 21, 22, or 23, whereby said subject mounts an immune response against HER-2/neu-expressing tumor, thereby treating, suppressing, or inhibiting a breast cancer in a subject.

3. A method of inducing a breast anti-tumor immune response in a subject comprising the step of administering to said subject a composition comprising a recombinant Listeria strain expressing a recombinant nucleotide sequence encoding a recombinant polypeptide comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) protein fused to a listeriolysin (LLO) protein, an ActA protein, or a PEST sequence, wherein said recombinant nucleotide sequence encoding said fragment is selected from the group consisting of SEQ ID NOs 21, 22, or 23, whereby said subject mounts an immune response against a HMW-MAA-expressing pericyte of a vasculature of said tumor, whereby said composition kills the vasculature of said tumor and induces the release of a tumor antigen, thereby inducing a breast anti-tumor immune response.

4. A method of delaying progression of a breast tumor in a subject, said method comprising the step of administering to said subject a composition comprising a recombinant Listeria strain expressing a recombinant nucleotide sequence encoding a recombinant polypeptide comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) protein fused to a listeriolysin (LLO) protein, an ActA protein, or a PEST sequence, wherein said recombinant nucleotide sequence encoding said fragment is selected from the group consisting of SEQ ID NOs 21, 22, or 23, whereby said subject mounts an immune response against a HMW-MAA-expressing pericyte of a vasculature of said tumor, whereby said subject mounts an immune response against a pericyte of a vasculature of said tumor, thereby delaying progression of a breast tumor in a subject.

5. A method of treating, suppressing, or inhibiting a breast cancer in a subject, whereby said cancer is associated with expression of HER-2/neu antigen in a subject, said method comprising the step of administering to said subject a composition comprising a recombinant Listeria strain expressing a recombinant nucleotide sequence encoding a recombinant polypeptide comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) protein fused to a listeriolysin (LLO) protein, an ActA protein, or a PEST sequence, wherein said recombinant nucleotide sequence encoding said fragment is selected from the group consisting of SEQ ID NOs 21, 22, or 23, whereby said subject mounts an immune response against a HMW-MAA-expressing pericyte of a vasculature of a tumor from said cancer, thereby treating, suppressing, or inhibiting a breast cancer in a subject.

6. A method of inducing a breast anti-tumor immune response in a subject comprising the step of administering to said subject a composition comprising a recombinant Listeria strain expressing a recombinant nucleotide sequence encoding a recombinant polypeptide comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) protein fused to a listeriolysin (LLO) protein, an ActA protein, or a PEST sequence, wherein said recombinant nucleotide sequence encoding said fragment is selected from the group consisting of SEQ ID NOs 21, 22, or 23, whereby said subject mounts an immune response against a HMW-MAA-expressing pericyte of a vasculature of said tumor, whereby said composition kills the vasculature of said tumor and induces the release of a tumor antigen, thereby inducing a breast anti-tumor immune response.

7. A method for treating breast tumor cells expressing HER-2/neu in a subject, said method comprising administering to said subject a composition comprising a recombinant Listeria strain expressing a nucleotide sequence encoding a recombinant polypeptide, said recombinant nucleotide sequence is encoded by SEQ ID NO: 23 linked to an LLO polypeptide.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 20, 2018
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047968/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2009
From: PATERSON, YVONNE; MACIAG, PAULO; SEAVEY, MATTHEW
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 022511/0979 →
Continuity (4)
Continuation In Part 11889715 · Aug 15, 2007
Provisional Application 60960538 · Oct 3, 2007
Provisional Application 60837608 · Aug 15, 2006
Related Publication 20090202587A1 · Aug 13, 2009